Case Details
- Citation: [2022] SGCA 64
- Title: Saridewi Binte Djamani v Public Prosecutor
- Court: Court of Appeal of the Republic of Singapore
- Date of Decision: 6 October 2022
- Judges: Sundaresh Menon CJ, Andrew Phang Boon Leong JCA, Tay Yong Kwang JCA
- Proceedings: Criminal Appeal No 30 of 2018; Criminal Motion No 15 of 2019
- Lower Court Reference: Criminal Case No 28 of 2018 (HC/CC 28/2018)
- Parties: Saridewi Binte Djamani (Appellant/Applicant) v Public Prosecutor (Respondent)
- Legal Area(s): Criminal Law; Misuse of Drugs Act offences; Criminal Procedure and Sentencing (admissibility of statements)
- Statutory Provision(s) Referenced: Misuse of Drugs Act (Cap 185, 2008 Rev Ed), ss 5(1)(a), 5(2), 17
- Related High Court Decisions: Public Prosecutor v Saridewi Bte Djamani and another [2018] SGHC 204 (Main Judgment); Public Prosecutor v Saridewi bte Djamani [2022] SGHC 150 (Remittal Judgment)
- Judgment Length: 16 pages; 3,920 words
- Key Issues on Appeal: Whether Saridewi’s “consumption” defence was credible for one packet (A1A2A); admissibility/weight of investigative statements in light of alleged methamphetamine withdrawal
- Fresh Evidence Motion: Criminal Motion No 15 of 2019 to adduce a medical report by Dr Rajesh Jacob dated 13 July 2019
- Cases Cited (as provided): [2003] SGCA 17; [2018] SGHC 204; [2022] SGCA 39; [2022] SGCA 64; [2022] SGHC 150
Summary
In Saridewi Binte Djamani v Public Prosecutor ([2022] SGCA 64), the Court of Appeal upheld the conviction and death sentence imposed on Saridewi for possession of diamorphine for the purpose of trafficking under ss 5(1)(a) and 5(2) of the Misuse of Drugs Act (Cap 185, 2008 Rev Ed) (“MDA”). The appeal centred on whether Saridewi could rebut the statutory presumption in s 17 of the MDA by establishing a credible “consumption” defence—specifically, whether a particular packet (marked A1A2A) was intended for her own consumption rather than trafficking.
Separately, Saridewi sought to adduce fresh medical evidence suggesting that her mental state was impaired at the time her statements were recorded during CNB investigations. The Court of Appeal, after remittal to the High Court for findings on methamphetamine withdrawal, concluded that even accepting moderate withdrawal, the evidence did not show that her ability to give reliable statements was compromised. The Court therefore dismissed the appeal, finding that the defence fell far short of the threshold required to rebut the s 17 presumption.
What Were the Facts of This Case?
The case arose from a CNB covert operation on 17 June 2016 in the vicinity of Block 350, Anchorvale Road. At about 3.35pm, a man named Muhammad Haikal Bin Abdullah (“Haikal”) arrived at the carpark on a motorcycle. After parking, he retrieved a white plastic bag from the motorcycle and took the lift to the 17th floor, where he met Saridewi and handed her a white plastic bag. In exchange, Saridewi gave Haikal an envelope marked “10.000”. After the exchange, both parties went their separate ways.
Shortly thereafter, Haikal was intercepted and arrested by CNB officers. Meanwhile, CNB officers moved towards Saridewi’s unit. When Saridewi heard their voices and movements outside her door, she suspected the presence of CNB officers and threw various items out of the kitchen window. CNB officers attempted to access the unit but were let in before they could fully break through. Saridewi was then arrested.
During the search of the unit and the surrounding vicinity, CNB officers seized multiple items associated with drug processing and distribution, including packets of crystalline substance, numerous glass tubes, a slab of tablets, empty packets and straws, unused envelopes, a digital weighing scale, and a heat sealer. They also seized communication devices and a notebook from Saridewi. From the adjacent construction site and the ground floor of Block 350, CNB recovered, among other things, a plastic bag containing two packets (A1A1 and A1A2), each containing granular powdery substance (A1A1A and A1A2A respectively). The recovery also included other packets and straws (including C1, D2A, and D3A) and a digital weighing scale (D5).
HSA analysis confirmed that the total diamorphine in Saridewi’s charge was 30.72g, comprising the diamorphine found in A1A1A, A1A2A, C1, D2A, and D3A. Saridewi’s defence at trial was that not all the diamorphine was meant for trafficking. Her position was that a substantial portion—particularly the packet marked A1A2A, which she described as “better quality”—was intended for her own consumption. The High Court rejected this defence and convicted her, imposing the death penalty. The present appeal and motion were therefore directed at both the credibility of the consumption defence and the admissibility/weight of her investigative statements.
What Were the Key Legal Issues?
The central legal issue in Criminal Appeal No 30 of 2018 was whether Saridewi had rebutted the statutory presumption under s 17 of the MDA. In practical terms, the Court had to assess whether her “consumption” defence was credible in light of the totality of circumstances, with particular focus on whether the packet A1A2A was intended for her personal use rather than trafficking.
A second, procedural and evidential issue arose from Criminal Motion No 15 of 2019. Saridewi sought leave to adduce fresh evidence in the form of a medical report by Dr Rajesh Jacob dated 13 July 2019. The report purported to show that Saridewi’s state of mind was impaired at the time her statements were taken. This raised the question whether any impairment due to methamphetamine withdrawal affected her ability to give reliable statements, and whether that would warrant excluding her statements or diminishing their weight.
Accordingly, the Court of Appeal had to consider both (i) the substantive threshold for rebutting the s 17 presumption through a consumption defence, and (ii) the evidential impact of psychiatric/medical evidence on the admissibility and reliability of investigative statements.
How Did the Court Analyse the Issues?
The Court of Appeal began by restating the correct legal approach to consumption defences under the MDA. It referred to the framework in Muhammad bin Abdullah v Public Prosecutor and another and emphasised that the court must examine the totality of the circumstances to determine whether an accused person has rebutted the statutory presumption. The relevant circumstances include the rate of consumption, the frequency with which the accused could and typically did obtain supply, the ability to afford drugs at the alleged rate, and whether there were admissions in the accused’s statements that the whole quantity was for sale.
Critically, the Court reaffirmed that the “key pillar and essential foundation” of a consumption defence is the rate of consumption. It relied on the clarification in A Steven s/o Paul Raj v Public Prosecutor ([2022] SGCA 39), explaining that other factors—such as financial ability, how the accused came to be in possession of the drugs, and possession of trafficking paraphernalia—are secondary. The Court reasoned that the rate of consumption is logically anterior: secondary factors flow from it. Therefore, the accused must establish the alleged rate with credible evidence. This principle was also linked to the evidential burden on the accused, as reflected in Sulaiman bin Jumari v Public Prosecutor ([2021] 1 SLR 557).
Turning to the fresh evidence motion, the Court addressed admissibility and reliability concerns. The remittal to the High Court required findings on whether Saridewi was suffering from methamphetamine withdrawal between 18 and 24 June 2016 (immediately after arrest) and whether that affected her ability to give reliable statements. The High Court, in the Remittal Judgment, found that Saridewi had at most mild to moderate withdrawal during the relevant period. The Court of Appeal accepted that moderate withdrawal could be assumed, but it held that the evidence did not establish that this affected her ability to give reliable statements.
The Court scrutinised the psychiatric evidence closely. It noted that while the defence expert, Dr Rajesh, opined that cognitive processes such as lack of focus and poor concentration and suggestibility can be affected by the severity of withdrawal, the expert did not tie those effects to Saridewi’s specific claims or identify which parts of her statements should be disregarded. The Court also found the defence expert’s response unhelpful because it did not explain how withdrawal symptoms translated into concrete unreliability in the statements. In addition, the Court observed that the surrounding evidence from doctors and nurses who examined Saridewi at the time did not show serious manifestations of withdrawal that would interfere with her ability to provide a statement.
Most importantly, the Court relied on contemporaneous clinical observations. Saridewi did not raise complaints or exhibit observable withdrawal symptoms to the four doctors who assessed her. The doctors did not observe signs of distress. She was able to respond and communicate lucidly and coherently, and she was observed to be alert and oriented. On that basis, the Court concluded that the High Court did not err in its handling of the statements. In other words, even if moderate withdrawal existed, it did not reach the threshold necessary to undermine the reliability of the investigative statements.
Having dealt with the evidential foundation, the Court returned to the substantive consumption defence. The Court’s reasoning indicates that Saridewi’s defence did not satisfy the “rate of consumption” requirement as the essential foundation. The Court also highlighted that Saridewi’s consumption defence shifted over time, undermining its credibility. The Court further considered the surrounding evidence, including the context of possession and the presence of trafficking paraphernalia, and found that these factors were inconsistent with a credible consumption narrative for the quantity and manner in which the diamorphine was possessed.
Although the appeal focused on one packet (A1A2A), the Court treated the defence as part of the broader inquiry into whether the statutory presumption had been rebutted. The Court concluded that the appeal fell “far short” of the threshold required to rebut the presumption in s 17. This meant that the consumption defence, even if partially plausible in isolation, could not overcome the statutory inference when assessed against the totality of circumstances and the evidential burden on the accused.
What Was the Outcome?
The Court of Appeal dismissed Criminal Appeal No 30 of 2018. It upheld Saridewi’s conviction and death sentence, finding that she failed to rebut the presumption under s 17 of the MDA. The Court held that her consumption defence—particularly regarding the packet marked A1A2A—was not supported by credible evidence establishing the foundational rate of consumption, and that the surrounding circumstances did not support the defence.
Criminal Motion No 15 of 2019 was also effectively dealt with through the remittal and subsequent findings. The Court concluded that the psychiatric/medical evidence did not warrant excluding Saridewi’s statements or otherwise undermining their reliability. As a result, the appeal was dismissed in full.
Why Does This Case Matter?
This decision is significant for practitioners because it reinforces the structured approach to consumption defences under the MDA. The Court’s emphasis on the “rate of consumption” as the “key pillar and essential foundation” provides a clear analytical starting point. Defence counsel must therefore focus on adducing credible evidence of consumption patterns and rates, rather than relying on secondary factors such as alleged “better quality” of drugs or general assertions of personal use.
Second, the case illustrates how courts evaluate psychiatric or medical evidence when it is invoked to challenge the reliability of investigative statements. Even where withdrawal symptoms exist, the court will look for a concrete link between the medical condition and the accused’s ability to provide reliable statements. General propositions about cognitive effects, without tying them to specific symptoms, specific statements, and observable clinical findings, are unlikely to succeed.
Finally, the case demonstrates the importance of consistency in an accused’s consumption narrative. Where the defence shifts, credibility is undermined, and the statutory presumption becomes harder to rebut. For law students and practitioners, Saridewi serves as a practical guide on how appellate courts scrutinise both evidential reliability and the substantive elements required to rebut s 17.
Legislation Referenced
Cases Cited
- [2003] SGCA 17
- Public Prosecutor v Saridewi Bte Djamani and another [2018] SGHC 204
- A Steven s/o Paul Raj v Public Prosecutor [2022] SGCA 39
- Saridewi Binte Djamani v Public Prosecutor [2022] SGCA 64
- Public Prosecutor v Saridewi bte Djamani [2022] SGHC 150
Source Documents
This article analyses [2022] SGCA 64 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.